Human Papilloma Virus
Cervical cancer (CC) is one of the most widely spread oncological pathologies that ranks second by the incidence in women in the world. Each year about 600 thousand of new CC cases are registered in the world with more than 250 thousand lethal outcomes. The virus nature of this cancer is confirmed by the World Health Organization and HPV is detected practically in 100 percent of cases of cervical precancer and cancer. Based on the frequency of detection of HPV genotypes from different grades of Cervical Intraepithelial Neoplasia (CIN Grades I-III), HPV genotypes are subdivided into High-risk HPV types (16, 18, 31 and 45), Intermediate-risk types (33, 35, 39, 51, 52, 56, 58, 59, and 68), and Low-risk types (6, 11, 42-44). Owing to the fact that the cervical cancer (CC) has a long development period and a fail-safe recognizable pre-clinic phase there is a possibility to detect and prevent the disease on its early stage.